

**Table S1.** Demographic and clinical characteristics of patients and controls.

Variables	Group		<i>p</i>	Patients group		
	Healthy subjects	SSc patients		dcSSc patients	lcSSc patients	<i>p</i>
N	14	40		23	17	
Age (Mean±SD)	48.3±7.8	48.9±14.5	0.769	52.1±12.0	46±16.1	0.099
ESR mm/h		16.5		20.5	14	
Median (min-max)	<12.0	(4-36)	NA	(7-36)	(4-21)	0.002**
CRP, mg/L		4.55		8.2	4.1	
Median (min-max)	<6.0	(1.1-14.8)	NA	(1.1-14.8)	(2.1-13.2)	0.245
mRSS median (min-max)	NA	16.9	NA	19.4	12.0	0.008*
		(8-37)		(8-37)	(9-24)	
Disease duration - >3 years from first non-RP n (%)	NA	32 (80)	NA	17 (74)	0	NA
Capillaroscopy						
Active n (%)		24 (60)		10 (43.6)	14 (82)	NA
Early n (%)	NA	5 (12.5)		5 (21.7)	0	NA
Late n (%)	NA	8 (20)		5 (21.7)	3 (18)	NA
Early/Active n (%)		3 (7.5)		3 (13)	0	NA
ANA positivity n (%)	NA	34 (85)	NA	23 (100)	11 (64)	NA
ATA n (%)	NA	7 (20.6)	NA	7 (30.4)	0	NA
ATA/ARA n (%)	NA	3 (8.8)	NA	0	3 (17)	NA
ACA n (%)	NA	4 (11.8)	NA	1 (4.3)	4 (23)	NA
ATA/ACA n (%)	NA	3 (8.8)	NA	3 (13)	0	NA
Organ involvement n (%)	NA	20 (50)	NA	14 (60.9)	6 (35.4)	NA
PAH n (%)	NA	2 (5)	NA	0	2 (11.8)	NA
IHD n (%)	NA	4 (10)	NA	2 (8.7)	2 (11.8)	NA
ILD n (%)	NA	3 (7.5)	NA	3 (13)	0	NA
GIT n (%)	NA	3 (7.5)	NA	2 (8.7)	1 (5.9)	NA
Multiple systems n (%)	NA	8 (20)	NA	7 (30.5)	1 (5.9)	NA
Lung fibrosis n (%)	NA	4 (10)	NA	4 (17.4)	0	NA
Treatment						
CCB n (%)	NA	6 (15)	NA	1 (4.3)	5 (29.4)	NA
ASA n (%)	NA	3 (7.5)	NA	1 (4.3)	2 (11.8)	NA
MTX n (%)	NA	4 (10)	NA	2 (8.7)	2 (11.8)	NA
CS n (%)	NA	3 (7.5)	NA	3 (13)	0	NA
AZA n (%)	NA	1 (2.5)	NA	1 (4.3)	0	NA
Combined n (%)	NA	23 (57.5)	NA	15 (65.4)	8 (47.1)	NA
Data for experimental variables						
	Healthy subjects	SSc patients	<i>p</i>	dcSSc patients	lcSSc patients	<i>p</i>
YKL-40 ng/ml (n)	(14) 44.52	(40) 76.58	0.004**	(23) 87.1	(17) 68.5	0.119
Median (min-max)	(28.15-70.81)	(21.64-310.5)		(21.64-310.5)	(24.32-264.7)	
CHI3L1	(12) 0.924	(31) 1.358	0.345	(19) 1.153	(12) 1.679	0.08
(n) Median FC (min-	(0.35-2.23)	(0.34-5.14)		(0.34-2.84)	(0.8-5.14)	

max)						
MALAT1 (n) Median FC (min-max)	(12) 1.058 (0.12-2.46)	(31) 1.952 (0.04-6.38)	0.049*	(19) 1.907 (0.04-4.39)	(12) 2.956 (0.796.38)	0.08
NEAT1 (n) Median FC (min-max)	(12) 1.072 (0.18-2.81)	(31) 2.328 (0.34-5.82)	0.008**	(19) 2.471 (0.34-4.79)	(12) 1.993 (0.37-5.82)	0.876
miR-30e (n) Mean FC (SD)	(12) 1.058 (0.338)	(31) 0.799 (0.398)	0.03*	(19) 0.829 (0.392)	(12) 0.765 (0.425)	0.613
miR-30a (n) Median FC (min- max)	(9) 0.972 (0.28-2.23)	(30) 0.411 (0.005-2.95)	0.01*	(16) 0.413 (0.005-1.88)	(14) 0.397 (0.06-2.95)	0.135

Systemic sclerosis – SSc; diffuse cutaneous systemic sclerosis – dcSSc; limited cutaneous systemic sclerosis – lcSSc, non-Rayno Phenomen – non-RP, ANA – anti-nuclear antibodies, ATA – anti-Scl-70 antibodies, ARA – anti-RNA polymerase antibodies, ACA – anti-centromere antibodies, RHF - right heart failure, GIT - gastrointestinal tract, IHD - ischemic heart disease, PAH - pulmonary arterial hypertension, ILD - interstitial lung disease, Calcium channel blockers – CCB, Acetylsalicylic acid – ASA, Methotrexate – MTX, Corticosteroids – CS, Azathioprin – AZA, \* statistical significance  $p < 0.05$ , \*\* statistical significance  $p < 0.01$ .